Henry Schein Earnings Today: The Beat Is the Easy Part. The Leadership Overhaul Is What Sets Up the Rest of 2026

Henry Schein reports Q2 earnings before the bell today. Analysts are penciling in non-GAAP EPS of $1.22 and revenue near $3.37 billion, which would be roughly 3.8% year-over-year growth. The company has reaffirmed its full-year 2026 guidance of $5.23 to $5.37 non-GAAP EPS and 3% to 5% sales growth at every quarterly stop since year-end.

If the headline simply says "beat and raise," you're reading the cover story, not the business. The more structural question is whether the new CEO's first major overhaul - announced four days before this earnings print - is beginning to show in the operating numbers, or whether today's report is the baseline the reorganization tries to improve.

The competitor angle around a beat-and-raise cycle is real but thin. Henry Schein has beaten estimates in Q1, Q3, and Q4 of 2025 and Q1 of 2026, missing only once over the trailing four quarters. The average surprise is 3.74%. A Q2 beat along that line keeps the streak alive but doesn't change the underlying factor profile. What changes the profile is what's happening behind the numbers.

Fred Lowery took the CEO post from Stanley Bergman in March, ending a 37-year tenure. Lowery comes from Thermo Fisher Scientific, where he ran laboratory products and bioproduction. His first substantive move came July 30: replacing the Executive Management Committee with a streamlined Henry Schein Leadership Team, integrating the global supply chain into the distribution group, and transitioning three longtime executives - COO Michael Ettinger, Chief Strategy Officer Mark Mlotek, and SVP of Global Supply Chain Jim Mullins - to senior advisor roles effective October 30. Evercore ISI's Elizabeth Anderson called it the most significant change at the company since Lowery arrived.

That restructuring matters because KKR, which gained roughly a 12% stake in May 2025 and was given the right to expand to 19.9% late last year, explicitly expected operating income improvements exceeding $200 million over the coming years. The supply-chain-to-distribution integration is the most concrete lever Lowery has pulled so far. Whether it reduces costs fast enough to support the guidance range - or pushes it higher - is what today's report and the accompanying commentary will test.

Now to the factor stack. Henry Schein trades at 24.9 times trailing earnings with a forward PE of 25.1. Its EV/EBITDA sits at 20.6x. On a standalone basis, those multiples are neither screaming value nor obviously stretched. But a number without a comparison set is just a number. The stock's own $9.86 billion market cap puts it in large-cap distribution territory, and the real question is whether it earns that multiple relative to what peers in healthcare supply and distribution are delivering.

Revenue growth is 5.6% year-over-year. That's above the 3% to 5% guidance midpoint, which is useful - it means the company has been running hotter than its own range. But it's not explosive growth, and the PEG ratio at 8.98 reflects that. This is a mature distributor, not a growth engine. The gross margin is 31.19%, operating margin is 4.93%, and EBITDA margin is 7.32%. Those are the thin-margin, high-volume numbers you'd expect from a supply chain operator. The path to the $200 million KKR improvement runs through operating margin, not top-line acceleration.

On the balance sheet, total debt stands at $6.48 billion with only $138 million in cash and equivalents. Net debt - total debt less cash, adjusted for other balance sheet items - comes to $2.22 billion. The debt-to-equity ratio of 49% is manageable. The current ratio is 1.36x and the quick ratio is 0.75x. Free cash flow over the trailing twelve months is $443 million, but it declined 17.7% year-over-year. That's the number to watch - cash conversion erosion in a business running $13 billion-plus in annual sales isn't trivial, even if operating cash flow of $578 million keeps things solvent.

Return on invested capital is 7.18%, return on equity is 10.56%. These are passable but not standout for a business of this scale. They're the kind of returns that justify a multiple in the 20-to-25x range only if the operating margin improvement thesis plays out. If margins stay flat, the current valuation is paying up for execution that hasn't arrived yet.

Technically, the stock is trading at $86.51, above its 50-day moving average of $82.06 and its 200-day moving average of $76.39. The RSI sits at 58.6 - bullish but not overextended. The stock is up 14.5% year-to-date and 30.8% over the rolling 12 months. It's not far from its 52-week high of $89.34. The MACD is positive at 0.93, and the 20-day volatility is a tight 2.30%. Momentum is supportive but not running hot. This isn't a stock where price action is telling you the move is over; it's telling you the trend is intact and the next catalyst matters.

AInvest's aggregate signal labels Henry Schein a Hold, with a composite analysis rating of 3.2, a fundamental rating of 8.12, and a liquidity rating of 7.5. That Hold rating aligns with what the factor stack shows: fundamentals are solid but the growth multiple is rich for a company whose operating leverage depends on a restructuring that's barely 45 days old.

Here's what the factor grades map to in plain English. Valuation is a C: 25x earnings for 5.6% growth and 4.9% operating margins is fair, not cheap. Growth is a C-plus: above the guidance range, but QoQ revenue actually declined 2.0% last quarter, and the FCF decline of 17.7% is a drag. Profitability is a C: 7.2% ROIC passes the bar but doesn't justify premium pricing. Safety is a B-minus: manageable leverage, thin liquidity cushion but no real distress risk. Momentum is a B: above both moving averages, RSI healthy, trend intact.

The portfolio role is clear. Henry Schein belongs in a dividend-adjacent, low-volatility distribution sleeve - not as a growth driver, but as a name where the upside case is operational execution under a new CEO with a PE owner pushing for margin gains. If Lowery's supply chain integration delivers even a portion of that $200 million operating income improvement, the current multiple could be re-rated higher. If the FCF decline continues or margins stagnate, the stock earns its Hold.

The trigger to watch isn't whether today's EPS beats by a cent or two - it already does that regularly. It's whether management uses the earnings call to quantify early benefits from the leadership reorganization, and whether the full-year guidance range moves above the current $5.23 to $5.37 ceiling. A raise above $5.37 is the signal that the restructuring thesis has substance, not just structure.